Clinical Trial Update: Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE) [Phase 3]

View source ↗

Summary

This update reports the completion of a Phase 3 Asian efficacy study of anifrolumab for active systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Active Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED